In addition, none of 2,163 children receiving the vaccine developed COVID-19, compared with four of 1,073 children given a dummy injection. The study showed that Spikevax produced a comparable antibody response in 12- to 17-year-olds to that seen in young adults (aged 18 to 25 years), as measured by the level of antibodies against SARS-CoV-2. The effects of Spikevax were also investigated in a study involving over 3,000 children aged 12 to 17 years. The trial also showed 90.9% efficacy in participants at risk of severe COVID-19, including those with chronic lung disease, heart disease, obesity, liver disease, diabetes or HIV infection. This means that the vaccine demonstrated a 94.1% efficacy in the trial.

The trial showed a 94.1% reduction in the number of symptomatic COVID-19 cases in the people who received the vaccine (11 out of 14,134 vaccinated people got COVID-19 with symptoms) compared with people who received dummy injections (185 out of 14,073 people who received dummy injections got COVID-19 with symptoms). People did not know whether they received the vaccine or the dummy injections.Įfficacy was calculated in around 28,000 people from 18 to 94 years of age who had no sign of previous infection. Half received the vaccine and half were given dummy injections. The trial involved around 30,000 people in total. A very large clinical trial showed that Spikevax, given as a two-dose regimen, was effective at preventing COVID‑19 in people from 18 years of age.

La mod emergency 4